Edgewise Therapeutics (NASDAQ:EWTX) Stock Rating Reaffirmed by Wedbush
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report)‘s stock had its “outperform” rating reiterated by research analysts at Wedbush in a report released on Wednesday, Benzinga reports. They currently have a $31.00 price objective on the stock. Wedbush’s target price indicates a potential upside of 78.37% from the stock’s previous close. EWTX has been the topic […]
More Stories
‘Alarming’ situation in Great Lakes Region of DR Congo
The situation in Africa’s Great Lakes Region, in particular the Democratic Republic of the Congo (DRC), has remained “alarming” amid...
Explainer: How UN peacekeepers meet the challenge of escalating conflict in Lebanon
The UN peacekeeping mission UNIFIL has been operating along the “Blue Line” which separates Lebanon and Israel since the 1970s,...
Israel: New law blocking UNRWA ‘would be a catastrophe’, Guterres warns
Two bills before the Israeli parliament could put a halt to the lifesaving operations of UN Palestine relief agency, UNRWA,...
Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target at $35.40
LENZ Therapeutics, Inc. (NASDAQ:LENZ – Get Free Report) has been assigned an average recommendation of “Buy” from the seven research...
Analysts Set Spirax-Sarco Engineering plc (LON:SPX) Price Target at GBX 9,158
Spirax-Sarco Engineering plc (LON:SPX – Get Free Report) has been given an average rating of “Reduce” by the eight ratings...
Markel Group Inc. (NYSE:MKL) Receives $1,626.83 Average Target Price from Analysts
Markel Group Inc. (NYSE:MKL – Get Free Report) has been assigned an average recommendation of “Hold” from the six brokerages...